| 5 mins | 30 mins | Hourly | Daily | Weekly |
|---|---|---|---|---|
| BUY | SELL | SELL | SELL | SELL |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MA5 | 0.93▲ | 0.93▲ | 0.94▼ | 1.19▼ | 1.20▼ |
| MA10 | 0.93▲ | 0.95▼ | 1.03▼ | 1.23▼ | 1.36▼ |
| MA20 | 0.93▲ | 1.04▼ | 1.13▼ | 1.32▼ | 1.58▼ |
| MA50 | 0.95▼ | 1.16▼ | 1.20▼ | 1.45▼ | 2.95▼ |
| MA100 | 1.06▼ | 1.21▼ | 1.28▼ | 1.64▼ | 3.79▼ |
| MA200 | 1.16▼ | 1.29▼ | 1.38▼ | 2.66▼ | 4.74▼ |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MACD | 0.003▲ | -0.006▼ | -0.024▼ | -0.024▼ | 0.032▲ |
| RSI | 50.132▲ | 22.806▼ | 23.393▼ | 28.382▼ | 28.287▼ |
| STOCH | 37.195 | 23.526 | 11.655▼ | 24.950 | 3.729▼ |
| WILL %R | -28.693 | -86.000▼ | -89.899▼ | -95.188▼ | -98.215▼ |
| CCI | 64.205 | -62.172 | -88.876 | -230.969▼ | -194.351▼ |
|
Tuesday, September 29, 2026 07:49 AM
Aldeyra Therapeutics intends to formally challenge the FDA’s March 2026 rejection of reproxalap for dry eye disease, with a Formal Dispute Resolution Request and meeting with the agency’s Office of ...
|
|
Tuesday, September 29, 2026 04:00 AM
Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated diseases, today announced ...
|
|
Monday, September 28, 2026 01:00 AM
A live audio webcast and slide presentation will be accessible from the “Investors & Media” section of the Aldeyra website at https://ir.aldeyra.com/ for 90 days following the event.
|
| date | open | high | low | close | volume |
|---|---|---|---|---|---|
| 05/10/26 | 1.18 | 1.185 | 0.8976 | 0.9237 | 7,012,025 |
| 02/10/26 | 1.31 | 1.31 | 1.15 | 1.17 | 2,264,465 |
| 01/10/26 | 1.26 | 1.305 | 1.195 | 1.29 | 1,211,432 |
| 30/09/26 | 1.34 | 1.35 | 1.22 | 1.23 | 1,648,821 |
| 29/09/26 | 1.17 | 1.44 | 1.16 | 1.32 | 5,411,595 |
| 28/09/26 | 1.18 | 1.22 | 1.15 | 1.16 | 1,000,124 |
| 25/09/26 | 1.23 | 1.28 | 1.195 | 1.205 | 643,780 |
| 24/09/26 | 1.35 | 1.35 | 1.22 | 1.22 | 838,696 |
| 23/09/26 | 1.40 | 1.40 | 1.33 | 1.35 | 629,923 |
| 22/09/26 | 1.37 | 1.40 | 1.3506 | 1.395 | 427,813 |
|
|
||||
|
|
||||
|
|